BRAF and Papillary Craniopharyngioma: Moreover, since most papillary craniopharyngiomas harbor the BRAF V600E oncogenic mutation [6], a novel alternative is drug inhibition of the encompassing mitogen-activated protein kinase (MAPK) pathway controlling cell division, differentiation, and invasion.